{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:38:17Z","timestamp":1772890697490,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100011531","name":"University of Alabama","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011531","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","oarsijournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoarthritis and Cartilage"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.joca.2020.03.017","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T21:40:49Z","timestamp":1587073249000},"page":"917-923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparative safety of flavocoxid vs prescription NSAIDs among osteoarthritis patients"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8907-8976","authenticated-orcid":false,"given":"J.R.","family":"Curtis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.K.","family":"Owensby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.joca.2020.03.017_bib1","series-title":"LIMBREL Product Information","year":"2017"},{"issue":"5","key":"10.1016\/j.joca.2020.03.017_bib2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.nutres.2009.04.003","article-title":"Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short-term randomized, double-blind pilot study","volume":"29","author":"Levy","year":"2009","journal-title":"Nutr Res"},{"issue":"10","key":"10.1016\/j.joca.2020.03.017_bib3","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s12325-010-0064-z","article-title":"Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: a randomized multicenter controlled trial in subjects with osteoarthritis of the knee","volume":"27","author":"Levy","year":"2010","journal-title":"Adv Ther"},{"key":"10.1016\/j.joca.2020.03.017_bib4","series-title":"FDA Alerts Consumers about Potentially Life-Threatening Health Problems Linked to Limbrel","year":"2017"},{"key":"10.1016\/j.joca.2020.03.017_bib5","series-title":"Clinical classifications software (CCS) for ICD-9-CM","year":"2017"},{"issue":"12","key":"10.1016\/j.joca.2020.03.017_bib6","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1093\/clinchem\/38.12.2414","article-title":"Standardization of glycohemoglobin determinations in the clinical laboratory: three years of experience","volume":"38","author":"Bodor","year":"1992","journal-title":"Clin Chem"},{"issue":"8","key":"10.1016\/j.joca.2020.03.017_bib7","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/pds.3470","article-title":"Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed Database","volume":"22","author":"Lo Re","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.joca.2020.03.017_bib8","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1513\/AnnalsATS.201704-288OC","article-title":"Epidemiology of hypersensitivity pneumonitis among an insured population in the United States: a claims-based cohort analysis","volume":"15","author":"Fernandez Perez","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"10.1016\/j.joca.2020.03.017_bib9","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/pds.1924","article-title":"Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population","volume":"19","author":"Wahl","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.joca.2020.03.017_bib10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ahj.2004.02.013","article-title":"Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records","volume":"148","author":"Kiyota","year":"2004","journal-title":"Am Heart J"},{"issue":"6","key":"10.1016\/j.joca.2020.03.017_bib11","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1681\/ASN.2006010073","article-title":"Validity of international classification of diseases, ninth revision, clinical modification codes for acute renal failure","volume":"17","author":"Waikar","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"25","key":"10.1016\/j.joca.2020.03.017_bib12","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.joca.2020.03.017_bib13","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"26","key":"10.1016\/j.joca.2020.03.017_bib14","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.joca.2020.03.017_bib15","unstructured":"PRIMUS Limbrel\u00ae Safety Update Letter. https:\/\/www.limbrel.com\/downloads\/fda_advisory_limbrel_safety_update_dear_doctor_november_2017.pdf. Accessed April 28, 2020."}],"container-title":["Osteoarthritis and Cartilage"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458420309791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458420309791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:52:37Z","timestamp":1761018757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1063458420309791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1063458420309791"],"URL":"https:\/\/doi.org\/10.1016\/j.joca.2020.03.017","relation":{},"ISSN":["1063-4584"],"issn-type":[{"value":"1063-4584","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative safety of flavocoxid vs prescription NSAIDs among osteoarthritis patients","name":"articletitle","label":"Article Title"},{"value":"Osteoarthritis and Cartilage","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joca.2020.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Osteoarthritis Research Society International. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}